Open-label Study of the Safety and Activity of Oprozomib in Patients With Hematologic Malignancies
Amgen
Amgen
Dana-Farber Cancer Institute
Sunesis Pharmaceuticals
Idera Pharmaceuticals, Inc.
National Cancer Institute (NCI)
Masonic Cancer Center, University of Minnesota
National Cancer Institute (NCI)
National Cancer Institute (NCI)